By Fineline Cube Huadong Medicine Co., Ltd. (SHE: 000963) announced that the clinical trial application for DR10624 injection, submitted by its subsidiary Zhejiang Doer Biotechnology Co., Ltd. (“Doer Bio”), has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).
Regulatory Milestone
| Component | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial authorization |
| Drug | DR10624 injection – globally first-in-class long-acting trispecific agonist |
| Indications | Adult HFpEF and HFrEF |
| Developer | Zhejiang Doer Biotechnology Co., Ltd. (subsidiary of Huadong Medicine) |
| Target Receptors | FGF21R, GCGR, and GLP-1R |
| Announcement Date | 14 Jul 2026 |
Drug Profile & Mechanism of Action
DR10624 – Triple-Targeting Metabolic Modulator
- Molecule Type: Long-acting trispecific agonist (first-in-class globally)
- Targets:
- Fibroblast growth factor 21 receptor (FGF21R) – metabolic regulation and anti-inflammatory effects
- Glucagon receptor (GCGR) – energy expenditure and glucose metabolism
- Glucagon-like peptide-1 receptor (GLP-1R) – insulin secretion and cardiovascular protection
- Innovation Status: Independently developed by Doer Bio with global first-in-class designation
- Therapeutic Rationale: Simultaneous activation of three complementary pathways addresses multiple pathophysiological mechanisms in heart failure
Existing Clinical Development Pipeline
- Phase III: Severe hypertriglyceridemia (SHTG) – advanced stage development
- Phase II: Metabolic dysfunction-associated steatotic liver disease/MASH (MASLD/MASH) – ongoing studies
- New Indication: HFpEF/HFrEF – newly approved for clinical trials
Heart failure affects over 64 million people globally, with HFpEF representing approximately 50% of cases and historically limited treatment options compared to HFrEF.
Market Opportunity & Strategic Context
| Therapeutic Area | Market Dynamics |
|---|---|
| Heart Failure Market | Global market valued at $12+ billion, with HFpEF segment representing significant unmet need due to lack of effective therapies |
| GLP-1 Class Competition | Intense competition from semaglutide (Wegovy/Ozempic), tirzepatide (Mounjaro/Zepbound), but trispecific approach offers differentiated mechanism |
| First-Mover Advantage | As a first-in-class trispecific agonist, DR10624 could establish new standard of care if clinical data supports superior efficacy |
| Metabolic-Cardiovascular Link | Addresses growing recognition of metabolic dysfunction as key driver in heart failure pathogenesis |
Strategic Implications
- Platform Validation: Success across multiple indications (SHTG, MASLD/MASH, heart failure) validates Doer Bio’s trispecific platform technology
- Commercial Synergies: Potential for combination pricing strategies across related metabolic-cardiovascular indications
- Global Expansion Potential: First-in-class status creates opportunities for international partnerships or direct global development
- Competitive Differentiation: Triple mechanism of action provides potential advantages over mono- and dual-agonists in development by competitors
- Investor Value Creation: Expansion into heart failure significantly increases peak sales potential beyond original metabolic disease focus
The convergence of metabolic and cardiovascular therapeutics represents one of biopharma’s most promising growth areas, with multi-agonist approaches gaining significant investor and scientific interest.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development, regulatory pathways, and commercial potential for DR10624. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.-Fineline Info & Tech